New attempts for central nervous infiltration of pediatric acute lymphoblastic leukemia

AbstractThe cure rate of acute lymphoblastic leukemia (ALL), the commonest childhood cancer, has been sharply improved and reached almost 90% ever since the central nervous system (CNS)-directed therapy proposed in the 1960s. However, relapse, particularly in the central nervous system (CNS), is still a common cause of treatment failure. Up to now, the classic CNS-directed treatment for CNS leukemia (CNSL) has been aslant from cranial radiation to high-dose system chemotherapy plus intrathecal (IT) chemotherapy for the serious side effects of cranial radiation. The neurotoxic effects of chemotherapy and IT chemotherapy have been reported in recent years as well. For better prevention and treatment of CNSL, plenty of studies have tried to improve the detection sensitivity for CNSL and prevent CNSL from happening by targeting cytokines and chemokines which could be key factors for the traveling of ALL cells into the CNS. Other studies also have aimed to completely kill ALL cells (including dormant cells) in the CNS by promoting the entering of chemotherapy drugs into the CNS or targeting the components of the CNS niche which could be in favor of the survival of ALL cells in CNS. The aim of this review is to discuss the imperfection of current diagnostic methods and treatments for CNSL, as well as new attempts which could be significant for better elimination of CNSL.
Source: Cancer and Metastasis Reviews - Category: Cancer & Oncology Source Type: research

Related Links:

This article reviews the current landscape of antibody-based and cellular immunotherapies under current clinical evaluation with an emphasis on active or soon-to-open phase 1 trials for children with relapsed/refractory AML. PMID: 31808843 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Abstract Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Vitamin D inadequacy is now an internationally recognized health problem. Some relation has been observed between Vitamin D insufficiency and poor outcome in ALL though evidence is limited. Methods: A prospective observational study was done including children (1-15 years) with newly diagnosed ALL. Vitamin D estimation was performed at baseline and at end of induction chemotherapy. Results: Ninety-three patients were recruited in the study. Majority of them belonged to lower socio-economic status (75.3%), and we...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
Conclusion: This case demonstrates the importance of a broad differential diagnosis for a child presenting with leg pain and fever. PMID: 31528139 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research
Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer. Therapies for paediatric ALL have improved such that more than 80% of patients survive to 5 years post-therapy, and most survive to adulthood. However, these ALL patients experience long-term side effects, which permanently affect their quality of life. Bone loss is the most common skeletal abnormality in paediatric ALL survivors, and 40% of patients experience a fracture before therapy completion. Reduced longitudinal growth (short stature) is another significant side effect of ALL therapy.
Source: Experimental Hematology - Category: Hematology Authors: Tags: 3129 Source Type: research
In this study,TCF3 ‐HLF mRNA was detectable at a high level during induction therapy in a newly diagnosed t(17;19) ‐ALL case, whileTCF3 ‐PBX1 mRNA was undetectable at the end of induction therapy in most newly diagnosed t(1;19) ‐ALL cases. Using 4 t(17;19)‐ALL and 16 t(1;19)‐ALL cell lines, drug response profiling was analyzed. t(17;19)‐ALL cell lines were found to be significantly more resistant to vincristine (VCR), daunorubicin (DNR), and prednisolone (Pred) than t(1;19)‐ALL cell lines. Sensitivities to three (Pred, VCR, andl‐asparaginase [l‐Asp]), four (Pred, VCR,l‐Asp, and DNR) and five (Pred, VC...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Acute lymphoblastic leukemia (ALL) is a significant cancer of children resulting from the clonal proliferation of lymphoid precursors with arrested maturation. Although chemotherapeutic approaches have been achieving successful remission for the majority of cases of childhood ALL, development of resistance to chemotherapy has been observed. Thus, new therapeutic approaches are required to improve patients prognosis. Therefore, we investigated the anticancer potential of curcumin in ALL. We tested a panel of B-precursor ALL (B-Pre-ALL) cell lines with various translocations after treatment with different doses of curcumin. ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
pozza Ruggiero The central nervous system (CNS) may be considered as a sanctuary site, protected from systemic chemotherapy by the meninges, the cerebrospinal fluid (CSF) and the blood-brain barrier (BBB). Consequently, parenchymal and CSF exposure of most antineoplastic agents following intravenous (IV) administration is lower than systemic exposure. In this review, we describe the different strategies developed to improve delivery of antineoplastic agents into the brain in primary and metastatic CNS tumors. We observed that several methods, such as BBB disruption (BBBD), intra-arterial (IA) and intracavitary chemo...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 8 May 2019Source: The Lancet HaematologyAuthor(s): Daniel A Mulrooney, Geehong Hyun, Kirsten K Ness, Nickhill Bhakta, Ching-Hon Pui, Matthew J Ehrhardt, Kevin R Krull, Deborah B Crom, Wassim Chemaitilly, Deokumar K Srivastava, Mary V Relling, Sima Jeha, Daniel M Green, Yutaka Yasui, Leslie L Robison, Melissa M HudsonSummaryBackgroundTreatment for childhood acute lymphoblastic leukemia has evolved over the past five decades, with moderation of traditional chemotherapy and radiotherapy and the introduction of targeted immune-based and cellular-based therapies. The affect of these changes on...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Rimjhim Sonowal, Vineeta GuptaIndian Journal of Cancer 2019 56(2):180-181 Severe hyperlipidemia (>1000 mg/dL) at initial presentation of acute lymphoblastic leukemia (ALL) is rare. Cases of hyperlipidemia during therapy for childhood ALL where they were secondary to L-asparaginase or steroids have been described. This is a case report of a one-and-half-year-old boy who presented to us with fever, abdominal distension, severe pallor, and hepatosplenomegaly. Although his investigations were suggestive of ALL, the initial blood samples were found to be grossly lipemic. The lipid profile was abnormal, showing severe hyper...
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Elda Pereira Noronha1†, Luísa Vieira Codeço Marques1†, Francianne Gomes Andrade1, Luiz Claudio Santos Thuler2, Eugênia Terra-Granado1, Maria S. Pombo-de-Oliveira1*† and the Brazilian Collaborative Study Group of Acute Leukemia‡ 1Pediatric Hematology-Oncology Program, Research Center, Instituto Nacional de Câncer, Rio de Janeiro, Brazil 2Clinical Research Division, Research Center, Instituto Nacional de Câncer, Rio de Janeiro, Brazil T-cell acute lymphoblastic leukemia (T-ALL) is a biologically heterogeneous malignancy, which reflects distinctive stages ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Brain | Cancer | Cancer & Oncology | Chemotherapy | Childhood Cancer | Leukemia | Neurology | Pediatrics | Study